U.S. State Topics
>> Access to Therapies
>> Healthcare Reform
>> Payer Cost Containment Strategies
>> Proclamations, Resolutions and Legislation
>> State Advocacy Handbook
Access to Therapies
PPTA works with member companies and stakeholders to obtain access to therapies, payer cost containment strategies and on issues centered around health care reform.
Comment Letters
<---> See Previous Comment Letters
Healthcare Reform
There are more than 45 million individuals in the United States that lack health insurance. Many states are discussing healthcare reform to address the problem of the uninsured in their state. PPTA will actively participate in these discussions to ensure that the unique health care needs of plasma protein therapies consumers are addressed.
Payer Cost Containment Strategies
PPTA remains committed to preventing cost containment measures from impacting patient access to life-saving therapies. Payers frequently use cost containment measures to reduce the impact of rising health care costs. Common strategies include reducing pharmacy reimbursement, requiring patient cost-sharing, and single source provider agreements.
Proclamations, Resolutions and Legislation
<---> See Previous <-->
State Advocacy Handbook
In addition to this information, consumer groups also should visit the
State Advocacy Handbook. PPTA developed this resource to help consumer groups advocate for patient access in their states and to provide information about key issues facing users of plasma protein therapies.
- PPTA Letter to the Honorable Beverly Earle, North Carolina House of Representatives, Regarding the Appropriations Act (SB 897) (June 2010)
- PPTA Letter to the Honorable Fran Pavley, California State Senate Regarding Support for SB 971 (February 2010)
- PPTA Letter to the Honorable Ron Richard, Speaker of the House, Missouri Regarding Support for HB 1525 (February 2010)
- PPTA Letter to the Chairmen of the Joint Committee on Public Health In Massachusetts Regarding Support for HB 2098, an Act Relevant to the Treatment of Hemophilia(November 2009)
- PPTA Letter to Illinois Governor Pat Quinn Regarding Support for the Bleeding Disorders Community (May 2009)
- PPTA Comment Letter to the DC Department of Health; Proposed Rule Creating Chapter 17, Pharmaceutical Education Program, of Title 22, of the District of Columbia Municipal Regulations (August 2008)
- PPTA Support Letter to the Massachusetts Senate Health Care Financing Committee; Vital Legislation for the Bleeding Disorders Community (H. 4574) (July 2008)
- PPTA Support Letter to the California Assembly Budget Sub-Committee; Proposed Budget Trailer Bill Language (May 2008)
- PPTA Comment Letter to the California Senate Health Committee; the “Hemophilia Standards of Care Act” (SB 1594) (March 2008)
- PPTA Comment Letter to the California Board of Pharmacy; Delay Implementation of California’s Pedigree Requirements (March 2008)
- PPTA Comment Letter to the California Board of Pharmacy; Regarding Pedigree Law Implementation (December 2007)
- State of Alabama Response to PPTA on Alabama Medicaid Program Decision to Implement Changes In Reimbursement of Hemophilia Factor VIII Therapies (November 2007)
- PPTA Letter to Office of Pharmacy in State of West Virginia on Reimbursement for A1P1 Products (October 2007)
- PPTA Support Letter for Vital Legislation for the Bleeding Disorders Community in Massachusetts (H.2155 and H.2071) (September 2007)
- PPTA Letter to Pennsylvania House Insurance Committee Chairman for the Enactment of HB 1105, the "Hemophilia Standards of Care Act" (June 2007)
- PPTA Comment Letter to Arkansas Medicaid Policy Program on Arkansas Hemophilia Management Program (June 2007)
- PPTA Comment Letter to Arizona Senate Committee on Health; IVIG hearing Update (March 2007)
- PPTA Comment letter on Deficit Reduction Act of 2005 (February 2007)
- PPTA Comment Letter to State of Alabama on Medicaid Program Decision to Implement Public Health Service Based Pricing for Reimbursement of Hemophilia Factor VIII Therapies (January 2007)
Proclamations, Resolutions and Legislation (continued)